Construction of the Rosalind Franklin Institute Hub

生命科学部门构成了英国经济的关键部分：它雇佣了超过22万人，对GDP和英国的贸易平衡做出了重大贡献，对于为患者开发尖端治疗方法至关重要。它得到了英国世界领先的健康和生命科学研究基地的支持。许多关键的研究突破反过来又得益于工程和物理科学(EPS)研究的进步--EPS研究提供了越来越复杂的仪器和方法，以支持对活体(从微生物到植物、动物和人体)和生物过程(包括疾病病理学和药物作用)的研究。这个生态系统所有部分的研发--从基础了解到应用研究到产品开发--对于实现长期经济增长和农业、食品安全、医疗保健和公共卫生的持续进步至关重要。历史上的创新模式往往是线性的，带有一定程度的偶然性。如果物理学家、工程师、生命科学家和行业大规模合作，颠覆性技术和科学突破将会加速。这是罗莎琳德·富兰克林研究所(RFI)的领域：在哈威尔科学和创新园区设有一个联络点(Hub)，与英国领先高等院校的正式Spokes建立联系，它将整合学术界和工业界的互补专业知识，创建一个在物理科学和生命科学相结合的方法开发方面的全国卓越中心。RFI将开发颠覆性的下一代成像技术，使我们对细胞和疾病生物学的理解逐步改变，并对某些疾病进行非侵入性诊断和治疗。它将为药物发现设计新的方法和战略--提高制药和农用化学品部门的研发效率，并支持更快、更具成本效益的治疗目前难以治愈的疾病的新药或新除草剂的开发。它将创造高价值的就业机会，保护和吸引外来投资，推动长期增长，并有助于实现政府的创新、工业和区域战略。高度的不确定性、严重的溢出效应以及需要多方协作，都导致私营部门相对于社会最优水平的投资不足。需要政府以RFI(2016-21年期间为7960万GB CDEL和2350万RDEL)的形式进行干预，以降低风险并加速早期发现和创新；并促进新技术颠覆性影响最终依赖的可用性和集成(因此也是现实世界的吸收)。

The Life Sciences sector forms a key part of the UK economy: it employs over 220,000 people, contributes significantly to GDP and UK balance of trade, and is crucial for developing leading-edge treatments for patients. It is underpinned by the UK's world-leading research base in the health and life sciences. Many key research breakthroughs are, in turn, enabled by advances in engineering and physical sciences (EPS) research - which provide ever more sophisticated instrumentation and methods to support the study of living organisms (from microbes to plants, animals and the human body) and biological processes (including both disease pathology and drug action).R&D across all parts of this ecosystem - from fundamental understanding to applied research to product development - is crucial for the delivery of long-term economic growth and continued advances in agriculture, food security, healthcare and public health. Historic models of innovation have often been linear, involving a degree of serendipity. Disruptive technologies and scientific breakthroughs will be accelerated if physical scientists, engineers, life scientists and industry work together, and at scale. This is the domain of the Rosalind Franklin Institute (RFI): with a focal point (Hub) at Harwell Science and Innovation Campus, linked to formal Spokes in leading HEIs across the UK, it will integrate complementary expertise from academia and industry to create a national centre of excellence for methods development at the convergence of the physical and life sciences. The RFI will develop disruptive next-generation imaging technologies that will enable step changes in our understanding of cell and disease biology, and the non-invasive diagnosis and treatment of some conditions. It will design new methods and strategies for drug discovery - enhancing R&D productivity in the pharmaceutical and agrochemical sectors and supporting faster, more cost-effective development of novel medicines for currently intractable diseases, or new herbicides. It will create high-value jobs, protect and attract inward investment, and drive long-term growth; and contribute to the delivery of the Government's innovation, industrial and regional strategies.The RFI will focus on high-risk, long-term R&D challenges. A high degree of uncertainty, significant spill-overs and the need for multi-party collaboration all contribute to under-investment by the private sector, relative to socially optimal levels. Government intervention - in the form of the RFI (£79.6m CDEL and £23.5m RDEL in the period 2016-21) - is needed to de-risk and accelerate early-stage discovery and innovation; and to foster the usability and integration (and therefore the real-world uptake) on which the disruptive impact of new technologies ultimately depends.